Urologix, Inc.
ULGX · OTC
3/31/2015 | 12/31/2014 | 9/30/2014 | 6/30/2014 | |
|---|---|---|---|---|
| Revenue | $3 | $3 | $3 | $3 |
| % Growth | -9.2% | 1.9% | -8.3% | – |
| Cost of Goods Sold | $1 | $2 | $2 | $2 |
| Gross Profit | $1 | $1 | $1 | $2 |
| % Margin | 46.9% | 47.5% | 48.4% | 48.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $2 |
| Sales & Mktg Exp. | $1 | $1 | $1 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $2 | $2 | $2 |
| Operating Income | -$0 | -$0 | -$0 | -$3 |
| % Margin | -5.5% | -4.4% | -8% | -103.5% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$4 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$0 | -$0 | -$0 | -$4 |
| % Margin | -12.5% | -11.6% | -14.5% | -107% |
| EPS | -0.016 | -0.016 | -0.02 | -0.17 |
| % Growth | 2.4% | 19.2% | 88.1% | – |
| EPS Diluted | -0.016 | -0.016 | -0.02 | -0.17 |
| Weighted Avg Shares Out | 22 | 22 | 21 | 21 |
| Weighted Avg Shares Out Dil | 22 | 22 | 21 | 21 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1.5% | -0.6% | -3.5% | -7.5% |